Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Proven Techniques for Reining In Supply Chain Costs

Proven Techniques for Reining In Supply Chain Costs Healthcare delivery in the United States is experiencing a period of extreme flux and uncertainty that is combining to escalate costs. It is compounded by a healthcare supply chain which is vast, complex and plagued with inefficiencies. Supply costs can account for 25-30% of a hospital’s operating…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Proven Techniques for Reining In Supply Chain Costs

Healthcare delivery in the United States is experiencing a period of extreme flux and uncertainty that is combining to escalate costs. It is compounded by a healthcare supply chain which is vast, complex and plagued with inefficiencies. Supply costs can account for 25-30% of a hospital’s operating budget. Supplies relate directly to the patient experience, making it difficult to always settle for the least expensive option. Consequently, hospitals are continually faced with the challenge of decreasing supply chain costs without compromising patient care.

Supply Chain and Physician Preference Items

The balance of cost and function may be most true with Physician Preference Items (PPI) that can account for up to 60% of supply spend. As individual physicians typically select those specific tools with which they are most comfortable, PPI products can be extremely varied across the hospital. This variance, coupled with the high cost of PPI products, makes it difficult for hospital administrators to reduce spend across their organization. In order to keep supply spend in check, healthcare administrators must work collaboratively with physicians and their established preferences to address the financial bottom line and efforts to reduce costs while also improving efficiencies. It’s a collective approach among all stakeholders to balance cost, quality and outcomes.

One opportunity to significantly reduce supply chain inefficiencies and costs is through product standardization. By eliminating the number of similar products, hospitals are able to negotiate more aggressively with vendors to achieve higher value. When it comes to PPI, consideration should be made to determine which items are “preference” driven versus clinically necessary.

Standardizing physician preference items requires involving physicians in the process and educating them with clinical and financial data of clinical utilization patterns, patient outcomes, and product costs and value. While a complex and involved process, the savings extracted from a strategic focus on PPI is well worth the time and investment. TPC is a proven leader in assessing PPI opportunities, collaborating with physicians, and developing successful PPI programs that reduce supply spend without compromising clinical quality or patient care.

TPC Focus on Supply Chain and Physician Preference Items

The TPC model enables hospitals to aggregate their volume to wield increased purchasing power. By drawing upon the combined expertise of Members, TPC gives physicians, nurses, pharmacists and other clinical specialists a method to evaluate products and assess their financial value, as well as their impact on the quality of care. We have found a niche in custom contracting for high-value, complex PPI categories, such as spine and cardiology. By initiating conversations with physicians early in the process we can more effectively evaluate and analyze differences across products and vendors.

TPC collaborates with Members to create a better understanding of the market landscape and drive better decision making. Together, we level-set technology across multiple manufacturers in complex categories and drive standardization in pricing. TPC works with Clinical Value Analysis Teams (CVATs) and Physician Sub-Committees (PSCs) comprised of clinical leaders from each Member facility. These groups offer functionally equivalent, cost-effective solutions to promote a culture of clinical excellence and financial stewardship for all TPC Members. Functional equivalence is determined by objective review of the product using specific, predetermined criteria, and not based on clinical or operational preference. The members of CVATs and PSCs are of vital importance as they serve as clinical advisors, initiative champions and provide clinical input into product decisions.

Through TPC’s custom contracts, Members have achieved significant savings in multiple product categories including, $3.45 million in Cardiac Rhythm Management, $3.5 million in Spinal Implants, and $1.6 million in Interventional Cardiology. As healthcare systems across the country are seeking ways to generate cost savings in the complex category of supply chain, the TPC collaborative model has proven results in reducing supply chain expenses, especially in the challenging area of PPI.

Stronger Together. Superior Results. To learn more about TPC services for supply chain savings, visit http://www.tpc1.com/supply-chain/ today!

Read more at tpc1.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512